TTC17 and cancer: Specifically, TTC17 deficiency enhanced the intrinsic sensitivity of cancer cells to rapamycin, paclitaxel, pirfenidone, palbociclib, cobimetinib, sorafenib tosylate, fluorouracil, NVP-LDE225, and oxaliplatin and diminished the sensitivity of cells to floxuridine, dasatinib monohydrate, and estramustine phosphate sodium (Fig. 6e).